AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million. As per information.
Recently founded and largely operated in secret, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences division.
Despite having fewer than 10 employees, the startup ordered a large-scale evaluation powered by its specialized platform, which uses AI to map drug research and development, identify new drug targets, and manage clinical regulatory strategies.
This acquisition serves as a highly attractive acquisition-appointment, securing top-tier talent working at the increasingly competitive intersection of machine learning and biology.
Coefficient’s founding team includes veterans of Evozyn and Paragon Biosciences, CEO Aris Theologis, CTO Nathan Frey, and co-founder Samuel Stanton, both of whom previously worked in machine learning at Roche’s Genentech.
After aggressively staffing its corporate development team last year, Anthropic is actively seeking data licensing deals and strategic acquisitions to deepen its vertical market penetration.
The integration of Coefficient Bio’s team, which reports to Eric Corderer-Abrams, head of Anthropic Healthcare, will strengthen a unit that already serves pharmaceutical giants including Sanofi (NASDAQ:SNY), Novo Nordisk (NYSE:NVO), AbbVie (NYSE:ABBV), and Genmab (NASDAQ:GMAB).
Anthropic has continuously laid the groundwork for this expansion. The company launched last October Cloud Life SciencesUpgrading your core models to integrate with industry-standard scientific tools like Benchling and BioRender.
By January, Anthropic expanded into a HIPAA Compliant Offering specialized features capable of working in a healthcare environment, drafting clinical trial protocols and preparing regulatory submissions.
Amid acquisitions, major pharmaceutical players are also currently struggling to secure access to advanced algorithms as part of critical infrastructure for next-generation therapeutic devices.
Just last week, Eli Lilly & Company (NYSE:LLY) committed to US$2.75 billion To expand its AI-powered drug design partnership with Insilico Medicine.
A few days ago, Eärendil Labs Secured US$787 million to fund its AI-generated drug pipeline in a private placement backed by Sanofi and Pfizer (NYSE: PFE), which currently boasts more than 40 programs.
don’t forget to follow @INN_LifeScience For real-time updates!
Securities Disclosure: I, Gian Liguid, do not have any direct investment interest in any of the companies mentioned in this article.
